SpyGlass Pharma, Inc. (SGP) Fair Value 2026

SGP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.4 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-28, SpyGlass Pharma, Inc. (SGP) trades at $26.42. QOC: 5.4/10. Value Trap Risk: 0/100 (SAFE). 1/13 models active.

Key Facts

Ticker
SGP
Price
$26.42
Quality Score
5.4/10
Value Trap Risk
0/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give SGP?

1 Intrinsic Value Models vs. Current Price ($26.42)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.73 -97.2%

All Models Active

All 1 models are displayed above.

What Is SpyGlass Pharma, Inc. (SGP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, SpyGlass Pharma, Inc.'s intrinsic value is estimated at $0.73. Trading at its current price of $26.42, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -97.2%.

What Do the Models Say About SGP?

1 of 13 models are currently active for SGP. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does SGP Rank in Biotechnology?

Among 625 Biotechnology stocks, SGP ranks #232 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For SpyGlass Pharma, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is SGP a Value Trap?

CirclFi's Value Trap algorithm assigns SGP a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for SpyGlass Pharma, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, SpyGlass Pharma, Inc. earns a quality score of 5.4/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SGP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SGP's 1 active models, average confidence is 41%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy SpyGlass Pharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PRMEPrime Medicine, Inc.QOC 5.4IMMPImmutep LimitedQOC 5.4ATRAAtara Biotherapeutics, Inc.QOC 5.4DNLIDenali Therapeutics Inc.QOC 5.4HELPCybin D/B/A Helus PharmaQOC 5.4HYPDHyperion DeFi, Inc.QOC 5.4VANIVivani Medical, Inc.QOC 4.7ADILAdial Pharmaceuticals, Inc.QOC 3.9ZYMEZymeworks Inc.QOC 6.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PRME · IMMP · ATRA · DNLI · HELP · HYPD · VANI · ADIL · ZYME · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SGP?

6 companies across all industries closest to SGP’s Quality of Company score of 5.4/10.

LINELineage, Inc.QOC 5.4RGTIRigetti Computing, Inc.QOC 5.4SBIGSpringBig Holdings, Inc.QOC 5.4KLXEKLX Energy Services Holdings, Inc.QOC 5.4CDZICadiz Inc.QOC 5.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LINE · RGTI · SBIG · KLXE · CDZI · NVDA

Where Does SGP Sit in CirclFi's Biotechnology Rankings?

SGP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About SpyGlass Pharma, Inc.’s Valuation?

What is SpyGlass Pharma, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for SpyGlass Pharma, Inc. (SGP). The Quality of Company score is 5.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SGP overvalued or undervalued right now?

At $26.42, 0 of 1 active models suggest SGP may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits SpyGlass Pharma, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.4 mean for SGP?

SpyGlass Pharma, Inc.'s QOC of 5.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SGP?

CirclFi analyzes SGP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SGP a value trap in 2026?

SpyGlass Pharma, Inc.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns SpyGlass Pharma, Inc. (SGP) a Quality of Company score of 5.4/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SGP/ · Methodology
Primary sources for this SGP valuation
  • Financial statements: SpyGlass Pharma, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001778922) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SGP as of ; valuations recomputed .